**Template Table of Contents for HPTN Study-Specific Procedures Manual**

1 Introduction

1.1 Sources of Procedural Information

1.2 Investigator Responsibilities

1.3 Study Activation Process

1.4 IRB/EC Submissions

2 Protocol

3 Documentation Requirements

3.1 Essential Documents

3.2 Participant Case History Documentation

3.3 Study Product Accountability, Chain of Custody, and Dispensing Documentation (if applicable)

3.4 Record Retention Requirements

3.5 Publications

4 Participant Accrual

4.1 Accrual Plan and Targets

4.2 Screening and Enrollment

4.2.1. Definition of Screening

4.2.2. Eligibility Determination

4.2.3. Definition of Enrollment

4.2.4. Screening and Enrollment Timeframe

4.2.5. Screening and Enrollment Logs

4.2.6. Assignment of Participant ID Numbers

4.2.7. Screening HIV Testing (and/or other key screening tests/procedures)

4.2.8. Random Assignment (if applicable)

4.3 Informed Consent (alternatively, informed consent procedures can be described in a separate section, i.e., Section 5)

5 Participant Follow-up

5.1 Study Follow-up Plan and Retention Targets

5.2 Types of Follow-up Visits

5.3 Follow-up Visit Scheduling

5.4 Follow-up Visit Procedures

5.5 Follow-up Visit Locations

5.6 Study Product Supply/Dispensing During Follow-Up

5.7 Follow-up HIV Testing (and/or other key follow-up tests/procedures)

5.8 Modified Follow-up Procedures (if any)

5.9 Participant Transfers

5.10 Resumption of Study Participation After Voluntary withdrawal (if applicable)

6 Visit Checklists

6.1 Use of Checklists

6.2 Sequence of Procedures

7 Participant Retention

7.1 Retention Definition(s)

7.2 Retention Requirements

7.3 Rationale for Retention Goals (optional)

7.4 Retention Plan/SOPs

7.5 Obtaining and Updating Locator Information

7.6 Participant Tracking Database (if applicable)

7.7 Retention Tips

8 Study Product Considerations (the content of this section will vary based on whether it is intended for pharmacy staff, non-pharmacy staff, or both; include relevant sections as needed)

8.1 Responsibilities and Obligations with Regard to Blinding

8.2 Product Receipt

8.3 Product Storage

8.4 Product Preparation

8.5 Product Dispensing

8.6 Product Administration (and/or Product Use Instructions for Participants)

8.7 Product Accountability

8.8 Product Returns

8.9 Product Destruction

9 Clinical (and/or Counseling) Considerations

(include subsections relevant to the study clinical procedures/outcomes)

10 Adverse Event Reporting and Safety Monitoring (if applicable)

10.1 Definitions and General Reporting Guidance

10.1.1. Adverse Event

10.1.2. Serious Adverse Event

10.1.3. Expedited Adverse Event

10.2 Adverse Event Terminology

10.3 Adverse Event Severity

10.4 Adverse Event Relationship to Study Product

10.5 Adverse Event Outcomes and Follow-up Information

10.6 Reporting Recurrent Adverse Events

10.7 Social Harms

10.8 Safety Monitoring, Review, and Oversight

10.9 Safety Distributions from DAIDS

10.10 DAIDS Toxicity Table

10.11 DAIDS EAE Reporting Manual (if not included in study protocol)

11 Laboratory Considerations

(include subsections relevant to the study lab procedures/outcomes)

12 Data Collection

(SCHARP provides this section in its entirety)

13 Data Communiqués

(SCHARP provides this section in its entirety)

14 Study Reporting Plan

(SCHARP provides this section in its entirety)